Portal de Periódicos da CAPES

Serologic and Molecular Biologic Methods for SARS-associated Coronavirus Infection, Taiwan

2004; Centers for Disease Control and Prevention; Volume: 10; Issue: 2 Linguagem: Inglês

10.3201/eid1002.030731

1080-6059

Ho-Sheng Wu, Shu‐Chun Chiu, Tsan-Chang Tseng, Szu-Fong Lin, Jih‐Hui Lin, Yu-Fen Hsu, Mei-Ching Wang, Tsuey‐Li Lin, Wen‐Zieh Yang, Tian-Lin Ferng, Kai‐Hung Huang, Li‐Ching Hsu, Li-Li Lee, Pan‐Chyr Yang, Hour‐Young Chen, Shun-Pi Su, Chih‐yu Shih, Ting-Hsiang Lin, Ih‐Jen Su,

SARS-CoV-2 detection and testing

Severe acute respiratory syndrome (SARS) has raised a global alert since March 2003. After its causative agent, SARS-associated coronavirus (SARS-CoV), was confirmed, laboratory methods, including virus isolation, reverse transcriptase-polymerase chain reaction (RT-PCR), and serologic methods, have been quickly developed. In this study, we evaluated four serologic tests ( neutralization test, enzyme-linked immunosorbent assay [ELISA], immunofluorescent assay [IFA], and immunochromatographic test [ICT]) for detecting antibodies to SARS-CoV in sera of 537 probable SARS case-patients with correlation to the RT-PCR. With the neutralization test as a reference method, the sensitivity, specificity, positive predictive value, and negative predictive value were 98.2%, 98.7%, 98.7%, and 98.4% for ELISA; 99.1%, 87.8%, 88.1% and 99.1% for IFA; 33.6%, 98.2%, 95.7%, and 56.1% for ICT, respectively. We also compared the recombinant-based western blot with the whole virus-based IFA and ELISA; the data showed a high correlation between these methods, with an overall agreement of >90%. Our results provide a systematic analysis of serologic and molecular methods for evaluating SARS-CoV infection.